UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005598
Receipt number R000004266
Scientific Title Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patients
Date of disclosure of the study information 2011/05/13
Last modified on 2011/05/13 15:59:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patients

Acronym

Novel combined therapy for chronic hepatitis C patients

Scientific Title

Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patients

Scientific Title:Acronym

Novel combined therapy for chronic hepatitis C patients

Region

Japan


Condition

Condition

chronic hepatitis type C

Classification by specialty

Hepato-biliary-pancreatic medicine Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We estimate safety as the effectiveness of the peginterferon alpha-2a (following PEG-IFN), Ribavirin (following RBV) and fluvastatin combination therapy for the chronic hepatitis C patient having the fatty liver.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

SVR rate(HCV RNA lasting negative)

Key secondary outcomes

SBR rate(ALT lasting normalization),the timing HCV RNA negative and adverse event


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Group A Fluvastatin(LOCHOL Tablets) 20~30mg/day is administered 12 weeks alone(The example of seriousness administers 60mg in the maximum).
Afterwards, administering of using together is done by the amount corresponding to weight it as for PEG-IFN (Pegasys)(once a week)and RBV(Copegas)(every day).
The HCV-RNA density in blood is measured once a month. Administering is extended until 72 weeks if it will not make gloomily by 12 weeks, and it will make it gloomily by 36 weeks.
Afterwards, it takes withdraw for 24 weeks, and the effect is judged.

Interventions/Control_2

Group B Administering of using together is done by the amount corresponding to weight it as for PEG-IFN (Pegasys)(once a week)and RBV(Copegas)(every day).
The HCV-RNA density in blood is measured once a month. Administering is extended until 72 weeks if it will not make gloomily by 12 weeks, and it will make it gloomily by 36 weeks.
Afterwards, it takes withdraw for 24 weeks, and the effect is judged.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient who applies to eligibility criteria for* by chronic hepatitis C (
Serogroup1(genotype1b)and the viral load in blood is HCV-RNA 5.0LogIU/ml or more).

*Patient with chronicity C type chronic hepatitis to which treatment resistance is expected by disorder of lipid metabolism(Patient who meets requirement more than one item either the following)
1.Triglyceride value 150mg/dL or more
2.Less than HDL cholesterol value 40mg/dL
3.Area 100cm3 or more of visceral fat
4.The female 25%or more by the body fat percentage man 22% or more.

Key exclusion criteria





Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name yoshiki murakami

Organization

Kyoto University Graduate School of Medicine

Division name

Center for Genomic Medicine

Zip code


Address

kyotoshi sakyouku shougoin kawaharatyou53

TEL

075-751-4192

Email



Public contact

Name of contact person

1st name
Middle name
Last name yoshiki murakami

Organization

Kyoto University Graduate School of Medicine

Division name

Center for Genomic Medicine

Zip code


Address

kyotoshi sakyouku shougoin kawaharatyou53

TEL

075-751-4192

Homepage URL


Email

ymurakami@genome.kyoto-u.ac.jp


Sponsor or person

Institute

Kyoto University Graduate School of Medicine
Center for Genomic Medicine

Institute

Department

Personal name



Funding Source

Organization

kagakukenkyuuhi

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 05 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2010 Year 07 Month 16 Day

Date of IRB


Anticipated trial start date

2010 Year 09 Month 01 Day

Last follow-up date

2014 Year 07 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 05 Month 13 Day

Last modified on

2011 Year 05 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004266


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name